Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 5069

Drug Profile

AZD 5069

Alternative Names: AZD-5069

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Antineoplastics; Small molecules
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary disorders; Head and neck cancer; Solid tumours
  • Phase I/II Pancreatic cancer; Prostate cancer
  • No development reported Bladder cancer; Non-small cell lung cancer
  • Discontinued Asthma; Bronchiectasis; Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Jul 2023 Astellas terminates a phase I/II trial in Prostate cancer (Metastatic disease, Hormone refractory, Combination therapy) in Switzerland and United Kingdom (PO) due to discontinuation in production of IMP (NCT03177187) (EudraCT2016-003141-28)
  • 29 Nov 2022 No development reported - Phase-II for Bladder cancer (Combination therapy) in USA (PO)
  • 29 Nov 2022 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top